Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Home > Investor Relations > Corporate Governance > Committee Composition

Committee Composition

  Audit Nominating and Corporate Governance Compensation
Luigi Lenaz,, MD   Committee Chair for Nominating and Corporate Governance Committee Member of Compensation Committee
Raymond W. Cohen Member of Audit Committee   Committee Chair for Compensation Committee
Stuart M. Krassner,, ScD, PsyD Member of Audit Committee    
Anthony E. Maida III,, PhD, MA, MBA Committee Chair for Audit Committee Member of Nominating and Corporate Governance Committee  
Anthony Maida III,

For 25 years, Dr. Maida has focused on the clinical development of immunotherapies to treat patients with cancer.

Dr. Maida is currently Senior Vice President – Clinical Research for Northwest Biotherapeutics, Inc., a cancer vaccine company focused on therapy of patients with glioblastoma multiforme and prostate cancer. Dr. Maida was formerly Vice President of Clinical Research and General Manager, Oncology, World-wide for PharmaNet, Inc. Prior to coming to Pharmanet, Dr. Maida served as Chairman, Founder and Director of BioConsul Drug Development Corporation and Principal of Anthony Maida Consulting International, servicing pharmaceutical firms, venture capital, hedge funds and Wall Street, in the clinical development of therapeutic products and product/company acquisitions.

Over the past 18 years Dr. Maida has served in a number of executive roles, including, Chairman, CEO, COO, CSO, CFO and business development. Dr. Maida was formerly the President and CEO of Replicon NeuroTherapeutics, Inc., a biopharmaceutical company focused on the therapy of patients with tumors (both primary and metastatic) of the CNS.

Prior to Replicon Dr. Maida served as Interim CEO for Trellis Bioscience, Inc. In 2000 Dr. Maida served as President of CancerVax Corporation. Over recent years Dr. Maida has raised, or assisted in financings, in excess of $200 million for start-up and emerging biotechnology companies. Dr. Maida was President and Chief Executive Officer of Jenner Biotherapies, Inc., and has served as Vice President of Finance and CFO for Lockheed DataPlan, a wholly owned subsidiary, and Senior Financial Controller of Lockheed Missiles, a $1.7 billion division, of Lockheed Missiles and Space Company.

Dr. Maida serves or has served on the advisory board of EndPoint BioCapital, Sdn Bhd (Kuala Lumpur, Malaysia), and as an advisor, consultant and technical analyst for CMX Capital, LLC, Sagamore Bioventures, Roaring Fork Capital, Toucan Capital, North Sound Capital, The Bonnie J. Addario Lung Cancer Foundation and Pediatric BioScience, Inc.

Dr. Maida holds a B.A. degree in Biology, a B.A. Degree in History, a MBA, a MA in toxicology and a Ph.D. in Immunology. He is a member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), the Society of Neuro-Oncology (SNO), the International Society for Biological Therapy of Cancer (iSBTc) and the American Chemical Society. Dr. Maida holds a number of patents and patent applications associated with various therapeutic modalities and approaches.


Dolatrai M. Vyas, PhD   Member of Nominating and Corporate Governance Committee Member of Compensation Committee
Committee Chair = Chair Committee Member = Member

Back to top

Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

NASDAQ: SPPI

Price:
9.45
Change:
- 0.36
Day High:
9.90
Day Low:
9.03
Volume:
1,947,261
4:00 PM ET on Sep 22, 2017
Delayed at least 20 minutes.
Provided by eSignal.

Shareholder Tools

Print Email

Search IR